Cutler Group LP Black Diamond Therapeutics, Inc. Transaction History
Cutler Group LP
- $307 Million
- Q1 2024
A detailed history of Cutler Group LP transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Cutler Group LP holds 700 shares of BDTX stock, worth $3,346. This represents 0.0% of its overall portfolio holdings.
Number of Shares
700
Previous 600
16.67%
Holding current value
$3,346
Previous $1,000
200.0%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding BDTX
# of Institutions
93Shares Held
36.5MCall Options Held
29.6KPut Options Held
5K-
Bellevue Group Ag Kuesnacht, V88.52MShares$40.7 Million0.68% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.73MShares$32.1 Million0.02% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$21.3 Million1.58% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.91MShares$9.11 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.6MShares$7.66 Million0.99% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $174M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...